Axsome Therapeutics, Inc. 8-K

What Happened
Axsome Therapeutics, Inc. announced on February 23, 2026 that it issued a press release reporting its financial results for the three months and fiscal year ended December 31, 2025 and providing an operational update. The company furnished the press release as Exhibit 99.1 to Form 8-K filed the same day. The Form 8-K was signed by President and CEO Herriot Tabuteau, M.D.

Key Details

• Date of filing and press release: February 23, 2026.
• Reporting periods: the three months and fiscal year ended December 31, 2025.
• Press release furnished as Exhibit 99.1 (and Inline XBRL cover page filed as Exhibit 104).
• Item reported under Form 8-K: 2.02 (Results of Operations and Financial Condition).

Why It Matters
This filing notifies investors that Axsome has publicly released its quarterly and full-year performance data and operational commentary. Retail investors should read the attached press release for the specific earnings figures (revenue, net income/loss, EPS), cash position, and any guidance or operational milestones announced, since those details affect valuation, near-term expectations, and investment decisions.